LOUISVILLE, CO--(Marketwire - November 01, 2007) - GlobeImmune, Inc. today announced that additional high dose results from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating GI-5005 as a treatment of chronic hepatitis C infection will be the subject of a poster presentation at the upcoming 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held in Boston at the John B. Hynes Convention Center from November 2-6, 2007.
